This retrospective study uses the Canadian LMC Diabetes Registry to describe the current health status of Canadians with type 1 diabetes. The study provides a detailed report of the demographic composition, treatment regimens, self-care approaches, health status, metabolic outcomes, and glycemic control of a large Canadian community-based, specialist-led cohort of patients with type 1 diabetes. Specific study outcomes will also be evaluated in a subgroup of patients using continuous subcutaneous insulin infusion (CSII) therapy.
Study Type
OBSERVATIONAL
Enrollment
3,600
LMC Healthcare
Toronto, Canada
HbA1c
HbA1c will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Fasting plasma glucose
Fasting plasma glucose will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Proportion of patients with HbA1c ≤7.0%, 7.1 to 8.0%, 8.1 to 9.0% and >9.0%
HbA1c will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Lipid parameters
Mean LDL cholesterol (mmol/L), mean HDL cholesterol (mmol/L), mean non-HDL cholesterol (mmol/L) and mean triglycerides (mmol/L) will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Proportion of patients below and above target LDL cholesterol
LDL cholesterol (mmol/L) will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Blood pressure
Mean systolic blood pressure (mmHg) and mean diastolic blood pressure (mmHg) will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 1 day
estimated glomerular filtration rate (eGFR)
Proportion of patients (%) with eGFR \<30 mL/min/1.73 m2, between 30-60 mL/min/1.73 m2, and \>60 mL/min/1.73 m2 will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Albuminuria
Proportion of patients (%) with urine albumin to creatinine ratio (uACR) \<2.0 mg/mmol and ≥ 2.0 mg/mmol will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Weight
Mean body weight (kg) will be measured by accessing patients medical records and it will be evaluated at one time point only.The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Body mass index (BMI)
Mean BMI (kg/m2) and proportion of patients (%) with BMI \<18.5, 18.5 to \<25, 25 to \<30 and ≥ 30 kg/m2, will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019.
Time frame: 1 day
Waist circumference
Mean waist circumference (cm) will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Thyroid stimulating hormone (TSH)
Mean thyroid stimulating hormone (µIU/mL) will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Alanine aminotransferase (ALT)
Mean ALT (U) will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Microvascular comorbidity
History of any of the following: retinopathy, neuropathy or nephropathy. The history will be accessed from the patients medical records.
Time frame: 1 day
Macrovascular comorbidity
History of any of the following: coronary artery disease, angina, cardiovascular disease, congestive heart failure, coronary vascular disease, myocardial infarction, coronary artery bypass grafting, angioplasty, cerebral vascular disease, stroke, cerebrovascular accident, peripheral vascular disease, atherosclerotic disease, intermittent claudication, aorto-femoral bypass or femoral popliteal bypass. The history will be accessed from the patients medical records.
Time frame: 1 day
Weekly incidence of any hypoglycemia
Self-reported weekly incidence of any hypoglycemia will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Yearly incidence of severe hypoglycemia
Self-reported yearly incidence of hypoglycemia will be measured by accessing patients medical records and it will be evaluated at one time point only. The value will be the last measured value for each patient between January 2015 and June 2019
Time frame: 1 day
Mental health comorbidity
History of any of the following: anxiety, depression, bipolar affective disorder, eating disorder, schizophrenia, sleep disorder. The history will be accessed from the patients medical records.
Time frame: 1 day
Erectile dysfunction
Proportion of males with erectile dysfunction. The medical history will be accessed from the patients medical records.
Time frame: 1 day
Insulin type
Proportion of patients (%) using rapid-acting, intermediate acting and long-acting insulin
Time frame: 1 day
Insulin therapy regimen
Proportion of patients (%) using multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII)
Time frame: 1 day
Pump model
Proportion of patients (%) using different types of pump models.
Time frame: 1 day
Adjunct diabetes therapies
Proportion of patients (%) using non-insulin diabetes therapies, including metformin, SGLT2 inhibitors, DPP4 inhibitors, and GLP-1 receptor agonists
Time frame: 1 day
Lipid lowering therapies
Proportion of patients (%) using lipid lowering therapies
Time frame: 1 day
Antihypertensive therapies
Proportion of patients (%) using antihypertensive therapies
Time frame: 1 day
Mental health therapies
Proportion of patients (%) using therapies for a mental health condition
Time frame: 1 day
Glucose meter use
Proportion of patients (%) using a blood glucose monitor
Time frame: 1 day
Continuous glucose monitor (CGM) use
Proportion of patients (%) using a CGM device or a flash glucose monitor device
Time frame: 1 day
Glucagon availability
Proportion of patients (%) using glucagon
Time frame: 1 day
Clinical outcomes stratified by age group
Age groups include 18-25 years, 26-49 years, and greater or equal to 50 years
Time frame: 1 day